ACAMPROSATE CALC DR 333 MG TAB
For 30 tablets
Pharmacies pay
$17.67 filed
30 × $0.58908 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23, 2026-09-30 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$22.74 filed
30 × $0.75787 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
1.3× estimated
Medicare paid 1.3× what pharmacies pay.
Part D averages every strength and form sold under “Acamprosate Calcium” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23, 2026-09-30 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$25.32 estimated
$17.67 + $2.65 (15%) + $5.00 fee per fill = $25.32
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23, 2026-09-30 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ACAMPROSATE CALC DR 333 MG TAB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “acamprosate calcium” and “acamprosate calcium enteric-coated”, as its NDCs’ listings variously write the nonproprietary name.
FDA gives its dosage form as tablet, delayed release and its route as oral.
FDA lists 7 labelers (the companies named on the label) for its NDCs, among them Mylan Pharmaceuticals Inc., Major Pharmaceuticals and American Health Packaging.
FDA lists no Established Pharmacologic Class for it.
The NADAC file of 2026-10-14 prices it under 8 NDCs (National Drug Codes); the FDA directory lists 7 of them.
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $17.67 for 30 tablets (30 × $0.58908 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; those prices took effect between 2026-09-23 and 2026-09-30. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.
What NADAC measures · Why 30 tablets · NADAC explanation codes
The 7 labelers
| Labeler | NDCs | Pharmacies pay per unit |
|---|---|---|
| American Health Packaging | 1 | $0.58908 per EA filed |
| Bionpharma Inc., | 1 | $0.58908 per EA filed |
| Glenmark Pharmaceuticals Inc., USA | 1 | $0.58908 per EA filed |
| Major Pharmaceuticals | 1 | $0.58908 per EA filed |
| Mylan Pharmaceuticals Inc. | 1 | $0.58908 per EA filed |
| Somerset Therapeutics, LLC | 1 | $0.58908 per EA filed |
| Zydus Pharmaceuticals (USA) Inc. | 1 | $0.58908 per EA filed |
| Not listed as a package in the FDA directory | 1 | $0.58908 per EA filed |
When these prices took effect
- 2026-09-30 · 1 NDC · $0.58908 per EA filed
- 2026-09-23 · 7 NDCs · $0.58908 per EA filed
All 8 NDCs, with labeler and price
- 00378-6333-80 · Mylan Pharmaceuticals Inc. · $0.58908 per EA · eff. 2026-09-23 filed
- 00904-7213-04 · Major Pharmaceuticals · $0.58908 per EA · eff. 2026-09-23 filed
- 60687-0121-25 · American Health Packaging · $0.58908 per EA · eff. 2026-09-23 filed
- 60687-0121-95 · not listed as a package in the FDA directory · $0.58908 per EA · eff. 2026-09-23 filed
- 68382-0569-28 · Zydus Pharmaceuticals (USA) Inc. · $0.58908 per EA · eff. 2026-09-23 filed
- 68462-0435-18 · Glenmark Pharmaceuticals Inc., USA · $0.58908 per EA · eff. 2026-09-23 filed
- 69452-0353-25 · Bionpharma Inc., · $0.58908 per EA · eff. 2026-09-23 filed
- 70069-0860-18 · Somerset Therapeutics, LLC · $0.58908 per EA · eff. 2026-09-30 filed
What Medicare paid
Medicare Part D paid $22.74 for 30 tablets, at an average of $0.75787 per EA in 2024 (2024-01-01 to 2024-12-31) for “Acamprosate Calcium”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 51,736 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ACAMPROSATE CALC DR 333 MG TAB labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Acamprosate Calcium / Acamprosate Calcium: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.